| __timestamp | Agios Pharmaceuticals, Inc. | Ionis Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 19120000 | 20140000 |
| Thursday, January 1, 2015 | 35992000 | 37173000 |
| Friday, January 1, 2016 | 50714000 | 48616000 |
| Sunday, January 1, 2017 | 71124000 | 108488000 |
| Monday, January 1, 2018 | 114145000 | 244622000 |
| Tuesday, January 1, 2019 | 132034000 | 287000000 |
| Wednesday, January 1, 2020 | 149070000 | 354000000 |
| Friday, January 1, 2021 | 121445000 | 186000000 |
| Saturday, January 1, 2022 | 121673000 | 151000000 |
| Sunday, January 1, 2023 | 119903000 | 232600000 |
| Monday, January 1, 2024 | 156784000 |
Cracking the code
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and innovation. Ionis Pharmaceuticals, Inc. and Agios Pharmaceuticals, Inc. have been navigating this financial landscape since 2014. Over the years, Ionis has consistently spent more on SG&A, peaking in 2020 with expenses nearly 2.4 times higher than Agios. However, Agios has shown a more stable trend, with a 2023 SG&A expense of approximately 120 million, reflecting a 6% decrease from its 2020 peak. In contrast, Ionis saw a significant reduction in 2021, dropping by 47% from the previous year, before rising again in 2023. This fluctuation highlights Ionis's dynamic approach to cost management. As both companies continue to innovate, their ability to optimize SG&A costs will be pivotal in maintaining their competitive edge.
Cost Management Insights: SG&A Expenses for Amgen Inc. and Agios Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Agios Pharmaceuticals, Inc.
Comparing SG&A Expenses: Walgreens Boots Alliance, Inc. vs Ionis Pharmaceuticals, Inc. Trends and Insights
Grifols, S.A. and Agios Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Ionis Pharmaceuticals, Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
Selling, General, and Administrative Costs: Ionis Pharmaceuticals, Inc. vs Xencor, Inc.
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or Agios Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Vericel Corporation vs Agios Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Agios Pharmaceuticals, Inc. vs Geron Corporation
Operational Costs Compared: SG&A Analysis of Agios Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.